ClinicalTrials.gov
ClinicalTrials.gov Menu

Clinical Diagnosis of Acute Porphyria

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01568554
Recruitment Status : Recruiting
First Posted : April 2, 2012
Last Update Posted : May 8, 2018
Sponsor:
Collaborators:
University of Texas
University of Alabama at Birmingham
Icahn School of Medicine at Mount Sinai
University of Utah
Carolinas Medical Center
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Rare Diseases Clinical Research Network
Information provided by (Responsible Party):
University of California, San Francisco

Brief Summary:
The purpose of this study is to test whether a focused questionnaire and laboratory tests can better define risk factors associated with possible genetic porphyria. The investigators hypothesize that the genetic carrier state of acute porphyria is distinctive enough that the Genetic Carrier Profile the investigators devise through this study will be useful in identifying carriers of genetic porphyria among the large population with undiagnosed abdominal pain.

Condition or disease
Hereditary Coproporphyria (HCP) Acute Intermittent Porphyria (AIP) Variegate Porphyria (VP)

Detailed Description:

The porphyrias are a group of genetic diseases caused by disturbances in the formation of heme, an essential component of hemoglobin and other proteins, leading to either acute (neurologic) and/or chronic (cutaneous) symptoms. Acute porphyria is often difficult to diagnose because symptoms may not be specific and, unless the patient is in an active attack, laboratory values typically may not be useful for diagnosing porphyria. The purpose of this study is to test whether a focused questionnaire and laboratory evaluation tool can better define risk factors associated with possible genetic porphyria. The goals of this study are:

  • To determine the presence and number of abnormal lab tests and porphyria-like symptoms in adult family members of the first person in a family who has been diagnosed with a disease of acute porphyria, 50% of whom are expected to carry the same genetic defect of the index case.
  • To devise a Genetic Carrie Profile that could be used to screen people in whom the diagnosis of porphyria is being considered.
  • To test the Profile in patients with symptoms suggestive of HCP and/or urine tests showing some elevation of porphyrins.
  • To explain other possible causes of minor increases in porphyrin levels in patients with recurrent abdominal pain who have not been diagnosed with porphyria

Study Type : Observational
Estimated Enrollment : 600 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Clinical Diagnosis of Acute Porphyria
Study Start Date : December 2011
Estimated Primary Completion Date : December 2018
Estimated Study Completion Date : December 2018


Group/Cohort
Group 1
Group 1 will include subjects 15 years of age or older who are a first-degree relative (child, sibling, parent, or grandparent) of an individual with genetically proven acute porphyria (AIP, HCP or VP), and have not had any previous genetic testing for porphyria themselves.
Group 2 (Not Yet Enrolling)
Group 2 will consist of subjects 15 years of age or older who have a history of clinical features suggestive of acute porphyria, such as such as abdominal, back or limb pain, recurrent nausea lasting days, reaction to medications, psychiatric history, or sun sensitivity, and an increase in urinary, fecal or serum porphobilinogen (PBG) and/or porphyrins.
Group 3
Subjects in Group 3 will participate in the "Follow Up Sub-Study." This group will include individuals who have been seen by one of the Porphyria Consortium physicians/investigators for suspicion of porphyria 10 or more years prior to study initiation, but were not given a diagnosis of porphyria at the time of their initial visit.



Primary Outcome Measures :
  1. Presence of positive biochemical features by first-line testing in subjects suspected of being a genetic carrier of acute porphyria [ Time Frame: Assessed once at baseline visit for all subjects ]
    All subjects will be assessed for any elevation of quantitative urine porphobilinogen (PBG).

  2. Presence of positive biochemical features by second-line testing in subjects suspected of being a genetic carrier of acute porphyria [ Time Frame: Assessed once at baseline visit for all subjects ]
    All subjects will be assessed for any elevations of fractionated quantitative urine porphyrins.

  3. Presence of positive biochemical features by second-line testing in subjects suspected of being a genetic carrier of acute porphyria [ Time Frame: Assessed once at baseline visit for all subjects ]
    All subjects will be assessed for any elevations and levels of fractionated quantitative fecal porphyrins.

  4. Clinical features suggestive of the acute porphyria carrier state [ Time Frame: Assessed once at baseline visit for all subjects ]
    Through a focused questionnaire, we will determine the typical duration of pain attacks.

  5. Acute porphyria genetic carrier state [ Time Frame: Assessed once at baseline visit for all subjects ]
    All subjects will undergo DNA analysis to detect a mutation in the HMBS, CPOX, or PPOX genes, respectively.

  6. Other possible causes of mildly elevated porphyrins and recurrent pain [ Time Frame: Assessed once during a one-time telephone or in-person interview ]
    Participants in the Follow-up Sub-study section of this protocol will be interviewed concerning other possible causes of mildly elevated porphyins and recurrent pain. These will be patients previously seen by the investigator who were deemed not to have porphyria.

  7. Presence of heavy metals [ Time Frame: Assessed once at baseline visit for all subjects ]
    All subjects will undergo a blood test to screen for the presence of heavy metals as a cause for minor elevations of porphyrin levels.

  8. Validity of Genetic Carrier Profile [ Time Frame: The profile will be tested once during the baseline visit for subjects in Group 2. ]
    The biochemical and clinical features of genetically proven but asymptomatic HCP will be tabulated and compared to subjects who are not genetic carriers. Its accuracy in predicting risk factors for HCP will be tested in subjects in Group 2.


Secondary Outcome Measures :
  1. Frequency of disease manifestations in genetically confirmed AIP and HCP [ Time Frame: Assessed annually for 5 years ]
    Subjects who are confirmed to have AIP and HCP will be assessed at annual follow up visits for the presence and frequency of porphyria symptoms.

  2. Prevalence of HCP in a population with elevation of urine coproporphyrin and pain symptoms. [ Time Frame: Assessed once enrollment and genetic testing of subjects in Group 2 are complete - after a 1-year recruitment and enrollment period. ]
    Based on the number of subjects in Group 2 determined by DNA analysis to have HCP, we will approximate the prevalence of HCP in a population with elevations in coproporphyrin and pain symptoms that are undiagnosed.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   15 Years and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Group 1:

Individuals who are first-degree relatives of a patient with one of the acute porphyrias (AIP, HCP, VP). They will complete questionnaires and laboratory tests, including genetic testing for porphyria. The data will be used to develop a clinical profile for the risk factors associated with the genetic carrier state.

Group 2:

Subjects who possibly have acute porphyria, but do not have a confirmed diagnosis based on genetic testing. They will serve to test the validity of the clinical index derived from Group 1.

Group 3:

Patients who have been seen by one of the Porphyria Consortium physicians/investigators 10 or more years ago, but were not given a diagnosis of porphyria. They will complete a questionnaire to determine whether they received a porphyria diagnosis, or another diagnosis that might explain the initial presentation.

Criteria

Group 1 Inclusion Criteria:

  • Be 15 years of age or older
  • Be a first-degree relative (child, sibling, parent, or grandparent) of an individual with genetically proven acute porphyria (AIP, HCP or VP)
  • Not have had any previous genetic testing for acute porphyria

Group 2 Inclusion Criteria:

  • Be 15 years of age or older
  • Have a history of suggestive clinical features, such as abdominal, back or limb pain, recurrent nausea lasting days, reaction to medications, psychiatric history, or sun sensitivity.
  • An increase in urinary, fecal or serum porphobilinogen (PBG) and/or porphyrins

Groups 1 and 2 Exclusion Criteria:

  • Have previously had genetic testing for acute porphyria
  • Have a history of "alarm" symptoms, such as anemia, unintentional weight loss, signs of GI (gastrointestinal) bleeding, or dysphagia (difficulty in swallowing).

Follow Up Sub-Study (Group 3) Inclusion Criteria:

  • Have been seen by one of the Porphyria Consortium physicians/investigators 10 or more years prior to study initiation
  • Had a slight increase in porphyrins during the initial visit
  • Not given a diagnosis of porphyria at the time of the visit

Follow Up Sub-Study (Group 3) Exclusion Criteria:

  • You have been seen by the Porphyria Consortium physician/investigator less than 10 years prior to study initiation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01568554


Contacts
Contact: Raaj Kapoor (415)476-8405 yuvraaj.kapoor@ucsf.edu
Contact: Sasan Zenhari (415) 476-5352 sasan.zenhariabharrodi@ucsf.edu

Locations
United States, Alabama
UAB Porphyria Center, University of Alabama at Birmingham Recruiting
Birmingham, Alabama, United States, 35294
Contact: Angelia Johnson    205-934-7332    angeliajohnson@uab.edu   
Principal Investigator: Ashwani K Singal, M.D.         
United States, California
UCSF Porphyria Center, University of California at San Francisco Recruiting
San Francisco, California, United States, 94143
Contact: Raaj Kapoor    415-476-8405    yuvraaj.kapoor@ucsf.edu   
Principal Investigator: D. Montgomery Bissell, M.D.         
United States, New York
Mount Sinai Porphyria Comprehensive Diagnostic & Treatment Center, Mount Sinai School of Medicine Recruiting
New York, New York, United States, 10029
Contact: Tanhushree Laud    212-659-1418    tanushree.laud@mssm.edu   
Principal Investigator: Robert J. Desnick, Ph.D., M.D.         
United States, North Carolina
Wake Forest University School of Medicine Recruiting
Winston-Salem, North Carolina, United States, 27157
Contact: Dee Faust    336-713-1442    delannin@wakehealth.edu   
Principal Investigator: Herbert L. Bonkovsky, M.D.         
United States, Texas
UTMB Porphyria Center, University of Texas Medical Branch Recruiting
Galveston, Texas, United States, 77555
Contact: Csilla Hallberg, M.D.    409-772-4661    challberg@utmb.edu   
Principal Investigator: Karl E. Anderson, M.D.         
United States, Utah
Porphyria Center, University of Utah Recruiting
Salt Lake City, Utah, United States, 84132
Contact: Sharada Dixit    801-581-6650    sharada.dixit@hsc.utah.edu   
Principal Investigator: John Phillips, M.D.         
Sponsors and Collaborators
University of California, San Francisco
University of Texas
University of Alabama at Birmingham
Icahn School of Medicine at Mount Sinai
University of Utah
Carolinas Medical Center
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Rare Diseases Clinical Research Network
Investigators
Study Chair: D. Montgomery Bissell, M.D. University of California at San Francisco
Principal Investigator: Karl E. Anderson, M.D. University of Texas
Principal Investigator: Joseph R. Bloomer, M.D. University of Alabama at Birmingham
Principal Investigator: Robert J. Desnick, Ph.D., M.D. Icahn School of Medicine at Mount Sinai
Principal Investigator: James P. Kushner, M.D. University of Utah
Principal Investigator: Herbert L. Bonkovsky, M.D. Carolinas Medical Center and HealthCare System

Additional Information:
Responsible Party: University of California, San Francisco
ClinicalTrials.gov Identifier: NCT01568554     History of Changes
Other Study ID Numbers: PC7204
1U54DK083909 ( U.S. NIH Grant/Contract )
First Posted: April 2, 2012    Key Record Dates
Last Update Posted: May 8, 2018
Last Verified: May 2018

Additional relevant MeSH terms:
Porphyrias
Porphyria, Erythropoietic
Porphyria, Acute Intermittent
Coproporphyria, Hereditary
Porphyria, Variegate
Metabolic Diseases
Skin Diseases, Genetic
Genetic Diseases, Inborn
Skin Diseases
Porphyrias, Hepatic
Liver Diseases
Digestive System Diseases